AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
major depressive disorder